A cost avoidance study of critical care pharmacists' interventions in a tertiary institution in Singapore

被引:1
作者
Chan, Lin En Jeremy [1 ]
Soong, Jie Lin [1 ,2 ]
Lie, Sui An [3 ]
机构
[1] Natl Univ Singapore, Dept Pharm, Singapore, Singapore
[2] Singapore Gen Hosp, Dept Pharm, Singapore, Singapore
[3] Singapore Gen Hosp, Dept Surg Intens Care, Div Anaesthesiol & Perioperat Med, Singapore, Singapore
关键词
cost avoidance; intensive care unit; pharmacist; pharmacy intervention; value; ADVERSE DRUG EVENTS; LENGTH-OF-STAY; INTENSIVE-CARE; ECONOMIC-IMPACT; ILL PATIENTS; CLINICAL PHARMACIST; RISK-FACTORS; UNIT; MORTALITY; ICU;
D O I
10.1093/ajhp/zxac340
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose The economic impact of critical care pharmacists in the intensive care unit (ICU) setting has not been evaluated in Singapore despite ICUs being high-cost areas. This study was conducted to determine the costs avoided as a result of pharmacists' interventions within multidisciplinary ICU teams in a tertiary hospital in Singapore. Methods A single-center, retrospective observational study of accepted pharmacists' interventions was conducted over 6 months in 2020. We adopted a previously published systematic approach to estimate the costs avoided by the healthcare system through pharmacists' interventions. Interventions were independently reviewed by a critical care pharmacist, an intensivist, and an investigator. Cost avoidance was calculated in terms of the additional ICU length of stay that would have resulted had a pharmacist not intervened as well as the direct cost savings achieved. Results There were 632 medication-related problems (MRPs) associated with the 527 accepted interventions, as some interventions involved multiple MRPs. The most common interventions included correcting inappropriate drug regimens (n = 363; 57%), recommending drug monitoring (n = 65; 10%) and addressing omission of drugs (n = 50; 8%). Over 6 months, gross cost avoidance and net cost avoidance achieved were $186,852 and $140,004, respectively, resulting in a ratio of potential monetary cost avoidance to pharmacist salary of 3.99:1. The top 3 interventions that resulted in the greatest cost avoidance were those that corrected inappropriate drug regimens ($146,870; 79%), avoided adverse drug events (ADEs) ($10,048; 5%), and led to discontinuation of medications without any indication ($7,239; 4%). Conclusion Pharmacists can reduce healthcare expenditure substantially through cost avoidance by performing various interventions in ICUs, particularly in the areas of correcting inappropriate drug regimens, avoiding ADEs, and discontinuing unnecessary medications.
引用
收藏
页码:267 / 283
页数:17
相关论文
共 107 条
  • [1] Comparison of deep learning with regression analysis in creating predictive models for SARS-CoV-2 outcomes
    Abdulaal, Ahmed
    Patel, Aatish
    Charani, Esmita
    Denny, Sarah
    Alqahtani, Saleh A.
    Davies, Gary W.
    Mughal, Nabeela
    Moore, Luke S. P.
    [J]. BMC MEDICAL INFORMATICS AND DECISION MAKING, 2020, 20 (01)
  • [2] Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study
    Al Sulaiman, Khalid
    Aljuhani, Ohoud
    Al Dossari, Maram
    Alshahrani, Asma
    Alharbi, Aisha
    Algarni, Rahmah
    Al Jeraisy, Majed
    Al Harbi, Shmeylan
    Al Katheri, Abdulmalik
    Al Eidan, Fahad
    Al Bekairy, Abdulkareem M.
    Al Qahtani, Nouf
    Al Muqrin, Mashael
    Vishwakarma, Ramesh
    Al Ghamdi, Ghassan
    [J]. CRITICAL CARE, 2021, 25 (01)
  • [3] Proton Pump Inhibitors Versus Histamine 2 Receptor Antagonists for Stress Ulcer Prophylaxis in Critically III Patients: A Systematic Review and Meta-Analysis
    Alhazzani, Waleed
    Alenezi, Farhan
    Jaeschke, Roman Z.
    Moayyedi, Paul
    Cook, Deborah J.
    [J]. CRITICAL CARE MEDICINE, 2013, 41 (03) : 693 - 705
  • [4] Attributable Length of Stay and Mortality of Major Bleeding as a Complication of Therapeutic Anticoagulation in the Intensive Care Unit
    Ayas, Najib T.
    Dodek, Peter M.
    Wang, Hong
    Fowler, Robert
    Wong, Hubert
    Norena, Monica
    [J]. JOURNAL OF PATIENT SAFETY, 2015, 11 (01) : 23 - 27
  • [5] The costs of adverse drug events in hospitalized patients
    Bates, DW
    Spell, N
    Cullen, DJ
    Burdick, E
    Laird, N
    Petersen, LA
    Small, SD
    Sweitzer, BJ
    Leape, LL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (04): : 307 - 311
  • [6] Extended-Infusion Cefepime Reduces Mortality in Patients with Pseudomonas aeruginosa Infections
    Bauer, Karri A.
    West, Jessica E.
    O'Brien, James M.
    Goff, Debra A.
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2013, 57 (07) : 2907 - 2912
  • [7] Bauer Seth R, 2016, Hosp Pharm, V51, P507, DOI 10.1310/hpj5107-507
  • [8] Borthwick Mark, 2019, J Intensive Care Soc, V20, P161, DOI 10.1177/1751143718769043
  • [9] Bosma BE, 2018, NETH J MED, V76, P115
  • [10] Bourne Richard S, 2014, Int J Pharm Pract, V22, P146, DOI 10.1111/ijpp.12046